Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, ...

The Bay Area born agtech company has been beefing up its local research presence and already has a manufacturing facility in the region.

Massive Bio, a leader in AI-enabled patient recruitment and oncology solutions, today announced a collaboration with OpenAI ...

Agreement facilitates flexible, scalable automated industrialized production of rese-cel for many thousands of patients per year at a cost per batch that is among the lowest in the industry ...

A patent-protected Lipo-Nano-emulsion platform that lets brands take clean-label SKUs from concept to physical sample ...

BIO-key® International, Inc. (Nasdaq: BKYI), a global leader in Identity and Access Management (IAM) and biometric ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

For this action, the firm cited the potential of Nuvation Bio’s glioma drug candidate, safusidenib. First, RBC Capital ...

Climb Bio plans to raise about $110 million through a private placement with institutional investors, involving shares and pre-funded warrants. The transaction, expected to close around April 29, 2026 ...